Balazs P, Gaspar K, Gergely H, Hajdu K, Hollo P, Koszoru K
Arch Dermatol Res. 2025; 317(1):291.
PMID: 39825944
PMC: 11742771.
DOI: 10.1007/s00403-024-03786-4.
Yew Y, Barbieri J, Chen S
JAAD Int. 2024; 17:86-93.
PMID: 39399334
PMC: 11471223.
DOI: 10.1016/j.jdin.2024.07.020.
Mickle A, Lozano-Ortega G, Gaudet V, Popoff E, Barbeau M, Mathieu S
Patient Prefer Adherence. 2024; 18:475-486.
PMID: 38410773
PMC: 10896105.
DOI: 10.2147/PPA.S450215.
Bindra J, Chopra I, Hayes K, Niewoehner J, Panaccio M, Wan G
Clinicoecon Outcomes Res. 2023; 15:739-752.
PMID: 37868649
PMC: 10590138.
DOI: 10.2147/CEOR.S428466.
Borre E, Chen S, Nicholas M
JID Innov. 2023; 3(3):100186.
PMID: 37252320
PMC: 10213960.
DOI: 10.1016/j.xjidi.2023.100186.
Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland.
Dymond A, Green W, Edwards M, Pont M, Gupta G
Pharmacoecon Open. 2023; 7(3):443-454.
PMID: 37012513
PMC: 10170011.
DOI: 10.1007/s41669-023-00410-5.
Health utilities for non-melanoma skin cancers and pre-cancerous lesions: A systematic review.
So C, Cust A, Gordon L, Morton R, Canfell K, Ngo P
Skin Health Dis. 2022; 1(3):e51.
PMID: 35663144
PMC: 9060093.
DOI: 10.1002/ski2.51.
Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms.
Meregaglia M, Tarricone R
Pharmacoecon Open. 2022; 6(4):595-603.
PMID: 35182375
PMC: 9283626.
DOI: 10.1007/s41669-022-00326-6.
Estimating utility value for female genital mutilation.
Alinia C, Piroozi B, Jahanbin F, Safari H, Mohamadi-Bolbanabad A, Kazemi-Karyani A
BMC Public Health. 2020; 20(1):811.
PMID: 32471405
PMC: 7260824.
DOI: 10.1186/s12889-020-08947-4.
Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a large-scale observational study analysing effects of diagnoses and disease progression.
Philipp-Dormston W, Muller K, Novak B, Stromer K, Termeer C, Hammann U
J Eur Acad Dermatol Venereol. 2017; 32(7):1138-1146.
PMID: 29150868
PMC: 6032898.
DOI: 10.1111/jdv.14703.
Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
Oh A, Tran D, McDowell L, Keyvani D, Barcelon J, Merino O
J Manag Care Spec Pharm. 2017; 23(6):653-664.
PMID: 28530525
PMC: 5960988.
DOI: 10.18553/jmcp.2017.23.6.653.
General measures and quality of life issues in psoriasis.
Sarkar R, Chugh S, Bansal S
Indian Dermatol Online J. 2016; 7(6):481-488.
PMID: 27990382
PMC: 5134161.
DOI: 10.4103/2229-5178.193908.
Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update.
Vale S, Hill D, Feldman S
Pharmacoeconomics. 2016; 35(2):177-190.
PMID: 27785771
DOI: 10.1007/s40273-016-0462-4.
Discrepancies between the Dermatology Life Quality Index and utility scores.
Rencz F, Baji P, Gulacsi L, Karpati S, Pentek M, Poor A
Qual Life Res. 2015; 25(7):1687-96.
PMID: 26684848
DOI: 10.1007/s11136-015-1208-z.
Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis.
Shih V, Ten Ham R, Bui C, Tran D, Ting J, Wilson L
J Skin Cancer. 2015; 2015:505302.
PMID: 26171248
PMC: 4478371.
DOI: 10.1155/2015/505302.
A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Tolley K, Kemmett D, Thybo S, Nasr R, Smethurst H
Eur J Health Econ. 2015; 17(3):287-304.
PMID: 25795391
DOI: 10.1007/s10198-015-0679-8.
Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin.
Stephens J, Gao X, Patel D, Verheggen B, Shelbaya A, Haider S
Clinicoecon Outcomes Res. 2013; 5:447-57.
PMID: 24068869
PMC: 3782516.
DOI: 10.2147/CEOR.S46991.
Assessing quality of life in older adult patients with skin disorders.
Farage M, Miller K, Sherman S, Tsevat J
Glob J Health Sci. 2012; 4(2):119-31.
PMID: 22980159
PMC: 4777045.
DOI: 10.5539/gjhs.v4n2p119.
Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece.
Avgerinou G, Bassukas I, Chaidemenos G, Katsampas A, Kosmadaki M, Kousoulakou H
BMC Dermatol. 2012; 12:10.
PMID: 22831458
PMC: 3420305.
DOI: 10.1186/1471-5945-12-10.
Measuring melasma patients' quality of life using willingness to pay and time trade-off methods in Thai population.
Leeyaphan C, Wanitphakdeedecha R, Manuskiatti W, Kulthanan K
BMC Dermatol. 2011; 11:16.
PMID: 22182399
PMC: 3280162.
DOI: 10.1186/1471-5945-11-16.